Claims for Patent: 8,673,581

Summary for Patent: 8,673,581

Title:	sCD40L and placental growth factor (PLGF) as biochemical marker combinations in cardiovascular diseases
Abstract:	The invention relates to novel markers of vascular inflammation and combinations thereof as diagnostic and prognostic tools in patients with cardiovascular diseases. The markers also act as tools that facilitate the selection of active ingredients for the treatment of such diseases, and finally act as starting points for the treatment of cardiovascular diseases. Furthermore, the invention relates to the creation of an individual risk profile of negative events that are associated with the progression of arteriosclerosis.
Inventor(s):	Zeiher; Andreas M. (Frankfurt am Main, DE), Heeschen; Christopher (Munich, DE), Dimmeler; Stefanie (Frankfurt am Main, DE), Hamm; Christian (Bad Homburg, DE)
Assignee:	Siemens Healthcare Diagnostics Products GmbH (Marburg, DE)
Application Number:	13/613,010
Patent Claims:	1. A method for diagnosing an acute cardiovascular disease comprising: (a) obtaining a biological sample from a patient to be analyzed; (b) measuring a concentration of placental growth factor (PlGF) in the sample; (c) comparing the results obtained in (b) for the biological sample with a PlGF concentration in at least one reference sample; (d) using the comparison to diagnose an acute cardiovascular disease. 2. The method of claim 1, wherein the acute cardiovascular disease is chosen from unstable angina, myocardial infarction, acute coronary syndromes, coronary arterial disease, and heart insufficiency. 3. The method of claim 1, further comprising administering a therapy if an acute cardiovascular disease is diagnosed, the therapy comprising administering at least one statin or at least one inhibitor of a glycoprotein IIb/III-receptor. 4. The method of claim 3, wherein the at least one inhibitor of a glycoprotein IIb/III-receptor is abciximab. 5. The method of claim 1, further comprising measuring a concentration of at least one additional marker selected from PAPP-A, soluble CD40-ligand (sCD40L), troponin T (TnT), MPO, NT-proBNP, VEGF, BNP, and IL-10 in the sample. 6. The method of claim 5, wherein a diagnosis of acute cardiovascular disease is indicated by: (i) a concentration of PlGF above a reference concentration of about 27.0 ng/l and a concentration of PAPP-A above a reference concentration of about 12.6 mIU/l; (ii) a concentration of PlGF above a reference concentration of about 27.0 ng/l and a concentration of sCD40L above a reference concentration of about 5.0 .mu.g/I; (iii) a concentration of PlGF above a reference concentration of about 27.0 ng/l and a concentration of TnT above a reference concentration of about 0.1 .mu.g/l; (iv) a concentration of PlGF above a reference concentration of about 27.0 ng/l and a concentration of VEGF above a reference concentration of about 300 ng/l; or (v) a concentration of PlGF above a reference concentration of about 27.0 ng/1 and a concentration of IL-10 below a reference concentration of about 3.5 ng/l. 7. A method of determining a prognosis for an acute cardiovascular disease comprising: (a) obtaining a biological sample from a patient to be analyzed; (b) measuring a concentration of PlGF in the sample; (c) comparing the results obtained in (b) for the biological sample with a PlGF concentration in at least one reference sample; (d) using the comparison to determine the prognosis of an acute cardiovascular disease. 8. The method of claim 7, wherein the acute cardiovascular disease is chosen from unstable angina, myocardial infarction, acute coronary syndromes, coronary arterial disease, and heart insufficiency. 9. The method of claim 7, further comprising administering a therapy for an acute cardiovascular disease if a negative prognosis is determined, the therapy comprising administering at least one statin or at least one inhibitor of a glycoprotein IIb/III-receptor. 10. The method of claim 9, wherein the at least one inhibitor of a glycoprotein IIb/III-receptor is abciximab. 11. The method of claim 7, further comprising measuring a concentration of at least one additional marker selected from PAPP-A, soluble CD40-ligand (sCD40L), troponin T (TnT), MPO, NT-proBNP, VEGF, BNP, and IL-10 in the sample. 12. The method of claim 11, wherein a negative prognosis for an acute cardiovascular disease is indicated by: (i) a concentration of PlGF above a reference concentration of about 27.0 ng/l and a concentration of PAPP-A above a reference concentration of about 12.6 mIU/l; (ii) a concentration of PlGF above a reference concentration of about 27.0 ng/l and a concentration of sCD40L above a reference concentration of about 5.0 .mu.g/l; (iii) a concentration of PlGF above a reference concentration of about 27.0 ng/l and a concentration of TnT above a reference concentration of about 0.1 .mu.g/l; (iv) a concentration of PlGF above a reference concentration of about 27.0 ng/l and a concentration of VEGF above a reference concentration of about 300 ng/l; or (v) a concentration of PlGF above a reference concentration of about 27.0 ng/l and a concentration of IL-10 below a reference concentration of about 3.5 ng/l. 13. A method of monitoring therapy for an acute cardiovascular disease in a patient, comprising: (a) obtaining a biological sample from a patient to be analyzed; (b) measuring a concentration of PlGF in the sample; (c) comparing the results obtained in (b) for the biological sample with a PlGF concentration in at least one reference sample; (d) using the comparison to monitor therapy for an acute cardiovascular disease to detect an improvement or lack thereof in a pathophysiological condition; as indicated by a change in the concentration of the PlGF; and (e) adjusting the therapy for an acute cardiovascular disease, if necessary, in light of the improvement or lack thereof detected in (d). 14. The method of claim 13, wherein the acute cardiovascular disease is chosen from unstable angina, myocardial infarction, acute coronary syndromes, coronary arterial disease, and heart insufficiency. 15. The method of claim 13, wherein the therapy comprises administering at least one statin or at least one inhibitor of a glycoprotein IIb/III-receptor. 16. The method of claim 15, wherein the at least one inhibitor of a glycoprotein IIb/III-receptor is abciximab. 17. The method of claim 13, further comprising measuring a concentration of at least one additional marker selected from PAPP-A, soluble CD40-ligand (sCD40L), troponin T (TnT), MPO, NT-proBNP, VEGF, BNP, and IL-10 in the sample. 18. The method of claim 17, wherein a lack of improvement in a pathophysiological condition is indicated by: (i) a concentration of PlGF above a reference concentration of about 27.0 ng/l and a concentration of PAPP-A above a reference concentration of about 12.6 mIU/l; (ii) a concentration of PlGF above a reference concentration of about 27.0 ng/l and a concentration of sCD40L above a reference concentration of about 5.0 .mu.g/l; (iii) a concentration of PlGF above a reference concentration of about 27.0 ng/l and a concentration of TnT above a reference concentration of about 0.1 .mu.g/l; (iv) a concentration of PlGF above a reference concentration of about 27.0 ng/I and a concentration of VEGF above a reference concentration of about 300 ng/l; or (v) a concentration of PlGF above a reference concentration of about 27.0 ng/l and a concentration of IL-10 below a reference concentration of about 3.5 ng/l. 19. A method of treating an acute cardiovascular disease, comprising: (a) obtaining a biological sample to be analyzed; (b) measuring a concentration of PlGF or soluble CD40-ligand (sCD40L) in the sample (c) comparing the results obtained in (b) for the biological sample with a PlGF concentration or a sCD40L concentration in at least one reference sample; and (d) administering at least one inhibitor of a glycoprotein IIb/III-receptor if the concentration of PlGF measured in (b) is greater than the PlGF concentration in the reference sample in (c), or if the concentration of sCD40L measured in (b) is greater than the sCD40L concentration in the reference sample in (c). 20. The method of claim 19, wherein the at least one inhibitor of a glycoprotein IIb/III-receptor is abciximab. 21. The method of claim 19, wherein the at least one inhibitor of a glycoprotein Milli-receptor is administered if the concentration of PlGF in the biological sample is above a reference concentration of about 27.0 ng/l of if the concentration of sCD40L in the biological sample is above a reference concentration of about 5.0 .mu.g/l. 22. The method of claim 19, wherein the acute cardiovascular disease is chosen from unstable angina, myocardial infarction, acute coronary syndromes, coronary arterial disease, and heart insufficiency.

Details for Patent 8,673,581

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2022-11-16